Neuropathological diagnosis of Alzheimer disease.

H. Wiśniewski,A. Robe,W. Zigman,W. Silverman

DOI: https://doi.org/10.1097/00005072-198911000-00001

1989-11-01

Abstract:

What problem does this paper attempt to address?

Middleware-Based Failure Detection and Recovery Services for Fault-Tolerant E-services

D. Reilly,R. Thompson,A. Taleb-Bendiab

DOI: https://doi.org/10.1109/DESE.2009.60

2009-12-14

Abstract:The runtime detection of failure and recovery from failure is a major challenge facing e-business and e-commerce applications. Different types of failure are well understood through the failure model, but the detection and differentiation between these failures still proves difficult at runtime. Even when failures are detected, recovery may be hindered as certain failures may mask the root cause failure making it difficult to elaborate a recovery strategy. Through this paper we describe a pragmatic approach to failure detection and recovery based on the combination of middleware-based instrumentation and control services. In particular, we describe the development of failure detection instruments and failure recovery control services using Jini middleware technology. The failure detection instruments are capable of identifying different failure types and failure recovery control services make use of failure patterns to activate appropriate recovery strategies
Osimertinib As Neoadjuvant Therapy in Patients with EGFR-mutant Resectable Stage II-IIIB Lung Adenocarcinoma (NEOS): A Multicenter, Single-Arm, Open-Label Phase 2b Trial.

Chao Lv,Wentao Fang,Nan Wu,Wenjie Jiao,Shidong Xu,Haitao Ma,Jia Wang,Rui Wang,Chunyu Ji,Shaolei Li,Yuzhao Wang,Shi Yan,Fangliang Lu,Yuquan Pei,Yinan Liu,Yue Yang

DOI: https://doi.org/10.1016/j.lungcan.2023.02.011

IF: 6.081

2023-01-01

Lung Cancer

Abstract:Objectives: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been approved for EGFR-mutant non-small-cell lung cancer (NSCLC). We aimed to evaluate the effi-cacy and safety of neoadjuvant osimertinib in patients with EGFR-mutant resectable locally advanced NSCLC. Materials and Methods: This single-arm, phase 2b trial (ChiCTR1800016948) was conducted at six centers in mainland China. Patients with a measurable stage IIA-IIIB (T3-4 N2) lung adenocarcinoma and EGFR exon 19 and/or 21 mutations were enrolled. The patients were treated with osimertinib 80 mg orally once per day for six weeks, followed by surgical resection. The primary endpoint was the objective response rate (ORR) assessed according to the Response Evaluation Criteria In Solid Tumors version 1.1. Results: Between October 17, 2018, and June 08, 2021, 88 patients were screened for eligibility. Forty patients were enrolled and treated with neoadjuvant osimertinib therapy. The ORR was 71.1 % (27/38) (95 % confidence interval: 55.2-83.0) in 38 patients who completed the 6-week osimertinib treatment. Thirty-two patients un-derwent surgery, and 30 (93.8 %) underwent successful R0 resection. Thirty (75.0 %) of 40 patients had treatment-related adverse events during neoadjuvant treatment, and three (7.5 %) had treatment-related adverse events of grade 3. The most common treatment-related adverse events were rash (n = 20 [50 %]), diarrhea (n = 12 [30 %]), and oral ulceration (n = 12 [30 %]). Conclusions: The third-generation EGFR TKI osimertinib, with satisfying efficacy and acceptable safety profile, could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC.
New 3 alpha-hydroxy steroid-nicotinamide-adenine dinucleotide oxidoreductase activity in crystalline enzyme preparations.

T. Pocklington,J. Jeffery

DOI: https://doi.org/10.1042/BJ1100028PA

IF: 3.766

1968-12-01

Biochemical Journal

Abstract:
Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

Chao Lyu,Wentao Fang,Haitao Ma,Jia Wang,Wenjie Jiao,Rui Wang,Nan Wu,Shi-Dong Xu,Yue Yang

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.8524

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:8524 Background: Neoadjuvant treatment has demonstrated efficacy in several types of cancer and is increasingly used for the treatment of early-stage cancers with the potential of cancer downstaging to enhance complete surgical resection and to improve clinical outcomes. Recent evidences have demonstrated that the neoadjuvant use of first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may provide clinically meaningful improvement in EGFRm non-small cell lung cancer (NSCLC) patients, however, limited data were reported on osimertinib, the third-generation EGFR-TKI, in the neoadjuvant setting. Here we present an interim analysis of osimertinib as neoadjuvant treatment for resectable EGFRm NSCLC. Methods: NEOS is a prospective, multi-center, single-arm study to evaluate the efficacy and safety of osimertinib as neoadjuvant treatment in resectable EGFRm (19del/L858R) lung adenocarcinoma. Eligible patients were treated with osimertinib 80 mg orally per day for six weeks followed by surgery. Assessment of response to neoadjuvant therapy was performed according to RECIST 1.1. The primary endpoint was response rate. Secondary endpoints included safety, R0 surgical resection rate, quality of life, major pathologic response (MPR) rate, pathological complete response (pCR) rate, and N2 downstaging rate. Results: As of Dec. 17, 2020, 18 eligible patients (median age 61 [range 46-73], 27.8% male, 22.2% ECOG PS 1) have been enrolled. Patients with clinical stages IIa, IIb, and IIIa (8th AJCC) accounted for 16.7%, 22.2% and 61.1%, respectively. Half (9/18) of the patients had EGFR exon 21 L858R mutations and the other half (9/18) had EGFR exon 19del mutations. Amongst all 15 patients who completed efficacy assessment after neoadjuvant osimertinib, the response rate (RR) was 73.3% (11/15) and the disease control rate (DCR) was 100% (15/15). R0 surgical resection was performed in 93.3% (14/15) patients. Pathological downstaging occurred in 53.3% (8/15) patients. 42.9% (3/7) of the patients with confirmed N2 lymph nodes experienced downstaging to N0 disease after receiving neoadjuvant osimertinib. One patient was identified with a pCR. Adverse events (AEs) were reported in 66.7% (12/18) of patients, with the most common AE being rash (8/18, 44.4%), oral ulceration (8/18, 44.4%), and diarrhea (5/18, 27.8%). No grade 3-5 AEs or serious AEs were reported. Conclusions: Interim analysis from this study indicated neoadjuvant osimertinib as an effective and feasible treatment in patients with resectable stage II-IIIB EGFRm NSCLC. The trial is ongoing and the final results will be provided in the future. Clinical trial information: ChiCTR1800016948.

oncology
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Margarita Majem,Jonathan W. Goldman,Thomas John,Christian Grohe,Konstantin Laktionov,Sang-We Kim,Terufumi Kato,Huu Vinh Vu,Shun Lu,Shanqing Li,Kye Young Lee,Charuwan Akewanlop,Chong-Jen Yu,Filippo de Marinis,Laura Bonanno,Manuel Domine,Frances A. Shepherd,Shinji Atagi,Lingmin Zeng,Dakshayini Kulkarni,Nenad Medic,Masahiro Tsuboi,Roy S. Herbst,Yi-Long Wu

DOI: https://doi.org/10.1158/1078-0432.ccr-21-3530

IF: 13.801

2022-01-10

Clinical Cancer Research

Abstract:PURPOSE: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). We report health-related quality of life (HRQoL) outcomes from ADAURA.PATIENTS AND METHODS: Patients randomized 1:1 received oral osimertinib 80 mg or placebo for 3 years or until recurrence/discontinuation. HRQoL (secondary endpoint) was measured using the Short Form-36 (SF-36) health survey at baseline, 12, and 24 weeks, then every 24 weeks until recurrence or treatment completion/discontinuation. Exploratory analyses of SF-36 score changes from baseline until week 96 and time to deterioration (TTD) were performed in the overall population (stage IB-IIIA; N = 682). Clinically meaningful changes were defined using the SF-36 manual.RESULTS: Baseline physical/mental component summary (PCS/MCS) scores were comparable between osimertinib and placebo (range, 46-47) and maintained to Week 96, with no clinically meaningful differences between arms; difference in adjusted least squares (LS) mean [95% confidence intervals (CI), -1.18 (-2.02 to -0.34) and -1.34 (-2.40 to -0.28), for PCS and MCS, respectively. There were no differences between arms for TTD of PCS and MCS; HR, 1.17 (95% CI, 0.82-1.67) and HR, 0.98 (95% CI, 0.70-1.39), respectively.CONCLUSIONS: HRQoL was maintained with adjuvant osimertinib in patients with stage IB-IIIA EGFRm NSCLC, who were disease-free after complete resection, with no clinically meaningful differences versus placebo, further supporting adjuvant osimertinib as a new treatment in this setting. See related commentary by Patil and Bunn, p. 2204.

oncology
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Yi-Long Wu,Thomas John,Christian Grohe,Margarita Majem,Sang-We Kim,Terufumi Kato,Konstantin Laktionov,Huu Vinh Vu,Zhijie Wang,Shun Lu,Kye Young Lee,Charuwan Akewanlop,Chong-Jen Yu,Filippo de Marinis,Laura Bonanno,Manuel Domine,Lingmin Zeng,Ajlan Atasoy,Masahiro Tsuboi,Jonathan W. Goldman,Frances A. Shepherd,Roy S. Herbst

DOI: https://doi.org/10.1016/j.jtho.2021.10.014

IF: 20.121

2022-03-01

Journal of Thoracic Oncology

Abstract:INTRODUCTION: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. Here, we report prespecified and exploratory analyses of adjuvant chemotherapy use and outcomes from ADAURA.METHODS: Patients with resected stages IB to IIIA EGFRm NSCLC were randomized 1:1 to receive osimertinib or placebo for 3 years. Adjuvant chemotherapy before randomization was not mandatory, per physician and patient choice. DFS in the overall population (IB-IIIA), with and without adjuvant chemotherapy, was a prespecified analysis. Exploratory analyses included the following: adjuvant chemotherapy use by patient age, disease stage, and geographic location; DFS by adjuvant chemotherapy use and disease stage.RESULTS: Overall, 410 of 682 patients (60%) received adjuvant chemotherapy (osimertinib, n = 203; placebo, n = 207) for a median duration of 4.0 cycles. Adjuvant chemotherapy use was more frequent in patients: aged less than 70 years (338 of 509; 66%) versus more than or equal to 70 years (72 of 173; 42%); with stages II to IIIA (352 of 466; 76%) versus stage IB (57 of 216; 26%); and enrolled in Asia (268 of 414; 65%) versus outside of Asia (142 of 268; 53%). A DFS benefit favoring osimertinib versus placebo was observed in patients with (DFS hazard ratio = 0.16, 95% confidence interval: 0.10-0.26) and without adjuvant chemotherapy (hazard ratio = 0.23, 95% confidence interval: 0.13-0.40), regardless of disease stage.CONCLUSIONS: These findings support adjuvant osimertinib as an effective treatment for patients with stages IB to IIIA EGFRm NSCLC after resection, with or without previous adjuvant chemotherapy.

oncology,respiratory system
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB–IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial

Thomas John,Christian Grohé,Filippo de Marinis,Terufumi Kato,Qun Wang,Wu-Chou Su,Jin Hyuk Choi,Virote Sriuranpong,Barbara Melotti,Jun Chen,Muna Albayaty,Marta Stachowiak,Sarah Taggart,Yi-Long Wu,Masahiro Tsuboi,Margarita Majem,Jonathan W. Goldman,Frances A. Shepherd,Mary J. Fidler,Roy S. Herbst

DOI: https://doi.org/10.1016/j.jtho.2023.05.015

IF: 20.121

2023-05-25

Journal of Thoracic Oncology

Abstract:Introduction In ADAURA, adjuvant osimertinib significantly improved disease-free survival versus placebo in resected stage IB–IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). We report in-depth analyses of three-year safety, tolerability, and health-related quality of life (HRQoL) from ADAURA. Methods Patients were randomized 1:1 to osimertinib 80 mg or placebo once-daily for up to 3 years. Safety assessments were performed at baseline, week 2, 4, 12, and every 12 weeks until treatment completion/discontinuation, and 28 days after treatment stopped. The Short Form-36 (SF-36) survey measured HRQoL at baseline, week 12, 24, and every 24 weeks until recurrence/treatment completion/discontinuation. Data cut-off: April 11, 2022. Results Safety and HRQoL analysis sets: osimertinib, n = 337 and n = 339; placebo, n = 343 each. Median (range) total exposure duration was longer with osimertinib versus placebo: 35.8 (0–38) versus 25.1 (0–39) months. Most adverse events (AEs) were first reported within 12 months of starting treatment (osimertinib 97%, placebo 86%). AEs leading to dose reduction/interruption/discontinuation were reported in 12/27/13% of patients with osimertinib; 1/13/3% with placebo. Stomatitis/diarrhea were the most common AEs leading to osimertinib dose reduction/interruption; interstitial lung disease was the most common leading to osimertinib discontinuation (per protocol). There were no differences in time to deterioration for SF-36 physical/mental component summaries between osimertinib and placebo. Conclusions No new safety signals were reported and HRQoL was maintained over 3 years of adjuvant osimertinib treatment. Combined with significant efficacy benefit, these data further support adjuvant osimertinib in stage IB–IIIA EGFRm NSCLC.

oncology,respiratory system
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst,Yi-Long Wu,Thomas John,Christian Grohe,Margarita Majem,Jie Wang,Terufumi Kato,Jonathan W. Goldman,Konstantin Laktionov,Sang-We Kim,Chong-Jen Yu,Huu Vinh Vu,Shun Lu,Kye Young Lee,Guzel Mukhametshina,Charuwan Akewanlop,Filippo de Marinis,Laura Bonanno,Manuel Domine,Frances A. Shepherd,Damien Urban,Xiangning Huang,Ana Bolanos,Marta Stachowiak,Masahiro Tsuboi

DOI: https://doi.org/10.1200/JCO.22.02186

IF: 45.3

2023-02-02

Journal of Clinical Oncology

Abstract:Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. PURPOSE The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106 ) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non–small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data. METHODS Overall, 682 patients with stage IB-IIIA (American Joint Committee on Cancer/Union for International Cancer Control, seventh edition) EGFR-mutated (exon 19 deletion/L858R) NSCLC were randomly assigned 1:1 (stratified by stage, mutational status, and race) to receive osimertinib 80 mg once-daily or placebo for 3 years. The primary end point was DFS by investigator assessment in stage II-IIIA disease analyzed by stratified log-rank test; following early reporting of statistical significance in DFS, no further formal statistical testing was planned. Secondary end points included DFS in stage IB-IIIA, overall survival, and safety. Patterns of recurrence and CNS DFS were prespecified exploratory end points. RESULTS At data cutoff (April 11, 2022), in stage II-IIIA disease, median follow-up was 44.2 months (osimertinib) and 19.6 months (placebo); the DFS HR was 0.23 (95% CI, 0.18 to 0.30); 4-year DFS rate was 70% (osimertinib) and 29% (placebo). In the overall population, DFS HR was 0.27 (95% CI, 0.21 to 0.34); 4-year DFS rate was 73% (osimertinib) and 38% (placebo). Fewer patients treated with osimertinib had local/regional and distant recurrence versus placebo. CNS DFS HR in stage II-IIIA was 0.24 (95% CI, 0.14 to 0.42). The long-term safety profile of osimertinib was consistent with the primary analysis. CONCLUSION These updated data demonstrate prolonged DFS benefit over placebo, reduced risk of local and distant recurrence, improved CNS DFS, and a consistent safety profile, supporting the efficacy of adjuvant osimertinib in resected EGFR-mutated NSCLC.

oncology
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

Roy S. Herbst,Masahiro Tsuboi,Tom John,Terufumi Kato,Margarita Majem,Christian Grohé,Jie Wang,Jonathan W. Goldman,Shun Lu,Wu-Chou Su,Filippo de Marinis,Frances A. Shepherd,Ki Hyeong Lee,Nhieu Le,Arunee Dechaphunkul,Dariusz M. Kowalski,Lynne Poole,Marta Stachowiak,Yuri Rukazenkov,Yi-Long Wu

DOI: https://doi.org/10.1200/jco.2023.41.17_suppl.lba3

IF: 45.3

2023-06-08

Journal of Clinical Oncology

Abstract:LBA3 Background: Osimertinib is a third-generation, central nervous system (CNS) active EGFR-TKI, that potently and selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. In the primary analysis from the Phase III ADAURA study (NCT02511106), adjuvant osimertinib demonstrated a clinically meaningful, statistically significant, and practice-changing disease-free survival (DFS) benefit vs placebo in patients with completely resected EGFRm (ex19del/L858R) NSCLC ± adjuvant chemotherapy. In an updated DFS analysis, with 2 years additional follow-up, DFS and CNS DFS benefit with adjuvant osimertinib were sustained (stage II–IIIA DFS hazard ratio [HR] 0.23; 95% confidence interval [CI] 0.18, 0.30; stage IB–IIIA DFS HR 0.27; 95% CI 0.21, 0.34; stage II–IIIA CNS DFS HR 0.24; 95% CI 0.14, 0.42), with a tolerable safety profile observed over the extended treatment duration. Here, we report the planned final overall survival (OS) analysis from ADAURA. Methods: Eligible patients (aged ≥18 years [≥20 in Japan and Taiwan], WHO PS 0/1 with completely resected EGFRm (ex19del/L858R) stage IB, II or IIIA [AJCC/UICC 7th edition] NSCLC; adjuvant chemotherapy allowed) were randomized 1:1 to osimertinib 80 mg once daily or placebo until disease recurrence, treatment completion (3 years), or a discontinuation criterion was met. The primary endpoint was investigator-assessed DFS in stage II–IIIA. Key secondary endpoints: DFS in stage IB–IIIA, OS and safety. Data cut-off: January 27, 2023. Results: Globally, 682 patients were randomized; osimertinib n=339, placebo n=343. Adjuvant osimertinib significantly improved OS vs placebo. In patients with stage II–IIIA disease, OS HR was 0.49 (95% CI 0.33, 0.73; p=0.0004; 100/470 events, 21% maturity); 5-year OS rate was 85% with osimertinib vs 73% with placebo. Median follow-up for OS in stage II–IIIA was 59.9 months (osimertinib) and 56.2 months (placebo). In the overall population (stage IB–IIIA), OS HR was 0.49 (95% CI 0.34, 0.70; p<0.0001; 124/682 events, 18% maturity); 5-year OS rate was 88% with osimertinib vs 78% with placebo, with a median follow-up for OS of 60.4 months (osimertinib) and 59.4 months (placebo). Median OS was not reached in either population or treatment group. Conclusions: Adjuvant osimertinib demonstrated an unprecedented, highly statistically significant and clinically meaningful OS benefit in patients with EGFRm stage IB–IIIA NSCLC after complete tumor resection, with or without adjuvant chemotherapy. ADAURA is the first global Phase III study to demonstrate a statistically significant DFS and OS benefit with targeted treatment for patients with EGFRm stage IB–IIIA NSCLC. Clinical trial information: NCT02511106 .

oncology
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study

Collin M Blakely,Anatoly Urisman,Matthew A Gubens,Claire K Mulvey,Greg M Allen,Stephen C Shiboski,Julia K Rotow,Turja Chakrabarti,D Lucas Kerr,Jacqueline V Aredo,Bianca Bacaltos,Megan Gee,Lisa Tan,Kirk D Jones,W Patrick Devine,Robert C Doebele,Dara L Aisner,Tejas Patil,Erin L Schenk,Trever G Bivona,Jonathan W Riess,Melissa Coleman,Johannes R Kratz,David M Jablons

DOI: https://doi.org/10.1200/JCO.24.00071

2024-09-10

Abstract:Purpose: To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA EGFR-mutated non-small cell lung cancer (NSCLC). Patients and methods: This was a multi-institutional phase II trial of neoadjuvant osimertinib for patients with surgically resectable stage I-IIIA (American Joint Committee on Cancer [AJCC] V7) EGFR-mutated (L858R or exon 19 deletion) NSCLC (ClinicalTrials.gov identifier: NCT03433469). Patients received osimertinib 80 mg orally once daily for up to two 28-day cycles before surgical resection. The primary end point was major pathological response (MPR) rate. Secondary safety and efficacy end points were also assessed. Exploratory end points included pretreatment and post-treatment tumor mutation profiling. Results: A total of 27 patients were enrolled and treated with neoadjuvant osimertinib for a median 56 days before surgical resection. Twenty-four (89%) patients underwent subsequent surgery; three (11%) patients were converted to definitive chemoradiotherapy. The MPR rate was 14.8% (95% CI, 4.2 to 33.7). No pathological complete responses were observed. The ORR was 52%, and the median DFS was 40.9 months. One treatment-related serious adverse event (AE) occurred (3.7%). No patients were unable to undergo surgical resection or had surgery delayed because of an AE. The most common co-occurring tumor genomic alterations were in TP53 (42%) and RBM10 (21%). Conclusion: Treatment with neoadjuvant osimertinib in surgically resectable (stage IA-IIIA, AJCC V7) EGFR-mutated NSCLC did not meet its primary end point for MPR rate. However, neoadjuvant osimertinib did not lead to unanticipated AEs, surgical delays, nor result in a significant unresectability rate.
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

Suresh S. Ramalingam,Terufumi Kato,Xiaorong Dong,Myung-Ju Ahn,Le-Van Quang,Nopadol Soparattanapaisarn,Takako Inoue,Chih-Liang Wang,Meijuan Huang,James Chih-Hsin Yang,Manuel Cobo,Mustafa Özgüroğlu,Ignacio Casarini,Dang-Van Khiem,Virote Sriuranpong,Eduardo Cronemberger,Xiangning Huang,Toon van der Gronde,Dana C. Ghiorghiu,Shun Lu

DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba4

IF: 45.3

2024-06-06

Journal of Clinical Oncology

Abstract:LBA4 Background: EGFR mutations occur in up to one-third of pts with unresectable stg III NSCLC. Consolidation durvalumab is standard of care (SoC) for pts who do not progress after concurrent CRT (cCRT), yet the benefit of consolidation immunotherapy specifically for EGFRm NSCLC remains uncertain, with limited data available. Osi, a 3rd-generation CNS-active EGFR-TKI, is recommended for EGFRm advanced/metastatic NSCLC and as adjuvant therapy for resectable EGFRm NSCLC. We report primary results from the global, double-blind, placebo (PBO)-controlled Phase 3 LAURA study (NCT03521154), assessing efficacy/safety of osi in unresectable stg III EGFRm NSCLC without progression after definitive CRT. Methods: Eligible pts: aged ≥18 years (≥20 in Japan), WHO PS 0/1, unresectable stg III EGFRm (Ex19del/L858R) NSCLC, had received definitive platinum-based cCRT/sequential CRT (sCRT) with no progression. Pts were stratified (cCRT vs sCRT; stg IIIA vs IIIB/IIIC; Chinese vs non-Chinese) and randomized 2:1 to receive osi 80 mg or PBO QD until progression (blinded independent central review [BICR]-confirmed)/discontinuation. Imaging, including brain MRI, was mandated at baseline, every 8 wks to wk 48, then every 12 wks, until progression by BICR. Open-label osi was offered after progression by BICR. Primary endpoint: progression-free survival (PFS; RECIST v1.1) assessed by BICR. Secondary endpoints included overall survival (OS) and safety. Data cut-off: January 5, 2024. Results: Overall, 216 pts were randomly assigned: osi n=143, PBO n=73. Baseline characteristics were generally balanced across osi/PBO arms: female 63/58%, stg IIIA 36/33%, IIIB 47/52%, IIIC 17/15%, Ex19del 52/59%. Osi significantly improved PFS by BICR vs PBO: HR 0.16; 95% CI 0.10, 0.24; p<0.001. Median PFS was 39.1 mo (95% CI 31.5, not calculable) for osi vs 5.6 mo (95% CI 3.7, 7.4) for PBO; 12-mo PFS rate was 74% (osi) vs 22% (PBO); 24-mo PFS rate was 65% (osi) vs 13% (PBO). Investigator-assessed PFS (HR 0.19; 95% CI 0.12, 0.29; nominal p<0.001) was consistent with PFS by BICR. PFS benefit was consistent across predefined subgroups. Interim OS analysis (20% maturity) showed a trend in favor of osi: HR 0.81; 95% CI 0.42, 1.56; p=0.530; 81% of pts (PBO arm) received osi after progression. All-causality AEs were reported in 98% vs 88% pts; ≥Grade 3 AEs in 35% vs 12%; serious AEs in 38% vs 15% for osi vs PBO, respectively. Radiation pneumonitis AEs (grouped term): 48% (osi) vs 38% (PBO), majority Grade 1/2. Any AEs leading to discontinuation were reported in 13% vs 5% for osi vs PBO, respectively. Conclusions: Osi after definitive CRT demonstrated a statistically significant and clinically meaningful improvement in PFS, for unresectable stg III EGFRm NSCLC, with no unexpected safety signals. These results establish osi as the new SoC for EGFRm NSCLC in this setting. Clinical trial information: NCT03521154 .

oncology
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Amin H Nassar,So Yeon Kim,Jacqueline V Aredo,Jamie Feng,Frances Shepherd,Chao Xu,David Kaldas,Jhanelle E Gray,Thomas J Dilling,Joel W Neal,Heather A Wakelee,Yufei Liu,Steven H Lin,Tariq Abuali,Arya Amini,Yunan Nie,Tejas Patil,Anastasiya Lobachov,Jair Bar,Bailey Fitzgerald,Yu Fujiwara,Thomas U Marron,Rohit Thummalapalli,Helena Yu,Dwight H Owen,John Sharp,Saira Farid,Pedro Rocha,Edurne Arriola,Angelica D'Aiello,Haiying Cheng,Ryan Whitaker,Kaushal Parikh,Yash Ashara,Luxi Chen,Kamya Sankar,Jeremy P Harris,Misako Nagasaka,Adanma Ayanambakkam,Ana I Velazquez,Meera Ragavan,Jessica J Lin,Zofia Piotrowska,Molly Wilgucki,Joshua Reuss,Heike Luders,Christian Grohe,Javier Baena Espinar,Ella Feiner,Salman R Punekar,Shruti Gupta,Ticiana Leal,David J Kwiatkowski,Raymond H Mak,Elio Adib,Abdul Rafeh Naqash,Sarah B Goldberg

DOI: https://doi.org/10.1016/j.jtho.2024.01.012

Abstract:Introduction: Durvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. The optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown. Methods: In this multi-institutional, international retrospective analysis across 24 institutions, we evaluated outcomes in patients with stage III EGFRmut NSCLC treated with concurrent CRT followed by consolidation therapy with osimertinib, durvalumab, or observation between 2015 and 2022. Kaplan-Meier method was used to estimate real-world progression-free survival (rwPFS, primary end point) and overall survival (secondary end point). Treatment-related adverse events (trAEs) during consolidation treatment were defined using Common Terminology Criteria for Adverse Events version 5.0. Multivariable Cox regression analysis was used. Results: Of 136 patients with stage III EGFRmut NSCLC treated with definitive concurrent CRT, 56 received consolidation durvalumab, 33 received consolidation osimertinib, and 47 was on observation alone. Baseline characteristics were similar across the three cohorts. With a median follow-up of 46 months for the entire cohort, the median duration of treatment was not reached (NR) for osimertinib (interquartile range: NR-NR) and was 5.5 (interquartile range: 2.4-10.8) months with durvalumab. After adjusting for nodal status, stage III A/B/C, and age, patients treated with consolidation osimertinib had significantly longer 24-month rwPFS compared to those treated with durvalumab or in the observation cohorts (osimertinib: 86%, durvalumab: 30%, observation: 27%, p < 0.001 for both comparisons). There was no difference in rwPFS between the durvalumab and the observation cohorts. No significant difference in overall survival across the three cohorts was detected, likely due to the limited follow-up. Any-grade trAE occurred in 52% (2 [6.1%] grade ≥3) and 48% (10 [18%] grade ≥3) of patients treated with osimertinib and durvalumab, respectively. Of 45 patients who progressed on consolidation durvalumab, 37 (82%) subsequently received EGFR tyrosine kinase inhibitors. Of these, 14 (38%) patients developed trAEs including five patients with pneumonitis (14%; 2 [5.4%] grade ≥3) and five patients with diarrhea (14%; 1 [2.7%] grade ≥3). Conclusions: This study suggests that among patients with stage III unresectable NSCLC with a sensitizing EGFR mutation, consolidation osimertinib was associated with a significantly longer rwPFS compared to durvalumab or observation. No unanticipated safety signals were observed with consolidation osimertinib.
Adjuvant Osimertinib in Patients with Stage IB to IIIA EGFR Mutation-Positive NSCLC after Complete Tumor Resection: ADAURA China Subgroup Analysis

Jie Wang,Yi-Long Wu,Shun Lu,Qun Wang,Shanqing Li,Wen-Zhao Zhong,Qiming Wang,Wei Li,Buhai Wang,Jun Chen,Ying Cheng,Hongbing Duan,Gaofeng Li,Li Shan,Yangbo Liu,Jing Liu,Xiangning Huang,Ana Bolanos,Jie He

DOI: https://doi.org/10.1016/j.jtocrr.2023.100621

2024-01-01

JTO Clinical and Research Reports

Abstract:Introduction: In Chinese patients with NSCLC, prevalence of EGFR-mutated (EGFRm) disease is high. In the global phase 3 ADAURA study (NCT02511106), adjuvant osimertinib was found to have a statistically significant and clinically meaningful improvement in disease -free survival (DFS) versus placebo in resected stage IB to IIIA EGFRm NSCLC. We present efficacy and safety data from a subgroup analysis of 159 Chinese patients enrolled in the People's Republic of China from ADAURA. Methods: In ADAURA, patients with completely resected stage IB to IIIA EGFRm (exon 19 deletion/exon 21 L858R) NSCLC were randomized 1:1 to receive osimertinib (80 mg once daily) or placebo for 3 years or until disease recurrence/ discontinuation. Adjuvant chemotherapy was permitted before randomization, per physician/patient choice. Primary end point was investigator -assessed DFS in stage II to IIIA disease; secondary end points included DFS in stage IB to IIIA (overall population), overall survival, healthrelated quality of life (HRQoL), and safety. Results: Of 682 patients enrolled globally, 159 patients in the People's Republic of China were included in this subgroup analysis (osimertinib n = 77; placebo n = 82). Baseline characteristics were balanced across the treatment arms. At data cutoff, stage II to IIIA DFS hazard ratio (HR) was 0.23 (95% confidence interval [CI]: 0.13-0.42; maturity 59%); stage IB to IIIA DFS HR was 0.29 (95% CI: 0.17-0.48; maturity 42%). At 13% maturity (21 deaths), HR for overall survival in the stage IB to IIIA population was 0.51 (95% CI: 0.21-1.20). HRQoL was maintained from baseline, and safety was consistent with the global population. Conclusions: In this population of Chinese patients from ADAURA, adjuvant osimertinib was found to have a clinically meaningful improvement in DFS versus placebo, with maintained HRQoL and a safety profile consistent with the global study population.
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih-Hsin Yang,Dae Ho Lee,Jong-Seok Lee,Yun Fan,Filippo de Marinis,Eiji Iwama,Takako Inoue,Jerónimo Rodríguez-Cid,Li Zhang,Cheng-Ta Yang,Emmanuel de la Mora Jimenez,Jianying Zhou,Maurice Pérol,Ki Hyeong Lee,David Vicente,Eiki Ichihara,Gregory J. Riely,Yiwen Luo,Diana Chirovsky,M. Catherine Pietanza,Niyati Bhagwati,Shun Lu,Michael Joseph Boyer,Rina Hui,Mark Wong,Andrew Mant,Phillip Parente,Thomas John,Sagun Parakh,Gilberto Castro,Gustavo Werutsky,Sergio Jobim de Azevedo,Fabio Andre Franke,Joilda Batista De Almeida Rego,Pedro Rafael Martins De Marchi,Gustavo Dix Junqueira,Fernanda Maris Peria,Leandro Brust,Parneet Cheema,Mark Doherty,Ambika Parmar,Ines B. Menjak,Natasha B. Leighl,Jason Agulnik,Shun Lu,Zhigang Han,Jiuwei Cui,Li Zhang,Ying Cheng,Gongyan Chen,Helong Zhang,Yu Yao,Chengping Hu,Qiming Wang,Xin Zhang,Yong Zhang,Jianying Zhou,Kejing Ying,Yun Fan,Yan Wang,Ziping Wang,Jifeng Feng,YingYing Du,Lin Wu,Cheng Huang,Xiangdong Zhou,Maurice Perol,Julien Domont,Corinne Lamour,Julien Dutilh,Youssef Oulkhouir,Virginie Westeel,Delphine Carmier,Bruno Coudert,Aurelie Lagrange,Dominique Spaeth,Stanislas Ropert,Daniel C. Christoph,Jens Kern,Hans-Georg Kopp,Frank Griesinger,Rainer Wiewrodt,Martin Wermke,Claas Wesseler,Annette Mueller,Gunther Vogel,Victor Lee,Chung Man James Ho,Siu Hong Oscar Chan,Sing Hung Lo,Shi Feng Jonathan Nyaw,Yu Chung Jacky Li,Jair Bar,Maya Gottfried,Julia Dudnik,Alona Zer,Mor Moskovitz,Mirjana Wollner,Ofer Rotem,Sivan Shamai,Noam Asna,Mhameed Kamel,Silvia Novello,Francesco Di Costanzo,Laura Doni,Francesca Mazzoni,Francesco Ferrau,Filippo de Marinis,Giuseppe Tonini,Domenico Galetta,Francovito Piantedosi,Fabiana Vitiello,Keisuke Kirita,Kiyotaka Yoh,Toshiaki Takahashi,Yuichiro Ohe,Yoshihiro Hattori,Isamu Okamoto,Takayasu Kurata,Hiroshige Yoshioka,Hideo Saka,Masahide Oki,Terufumi Kato,Hiroshi Tanaka,Toru Kumagai,Takako Inoue,Toyoaki Hida,Yoshitsugu Horio,Shunsuke Teraoka,Eiki Ichihara,Kazuma Kishi,Hisashi Takaya,Daiya Takai,Toshiyuki Kozuki,Kazuo Kasahara,Yuichi Tambo,Yukio Hosomi,Masashi Kondo,Masao Ichiki,Hiroaki Takeoka,Emmanuel de la Mora Jimenez,Carlos Alberto Hernandez,Jeronimo Rafael Rodriguez Cid,Oscar Gerardo Arrieta Rodriguez,Ji-Youn Han,Young Joo Min,Dong-Wan Kim,Keunchil Park,Se-Hoon Lee,Ki Hyeong Lee,Jong-Seok Lee,Jin Hyoung Kang,Dae Ho Lee,Eun Kyung Cho,Enric Carcereny,Pilar Garrido Lopez,Margarita Majem Tarruella,Luis Paz-Ares Rodriguez,David Vicente Baz,Enriqueta Felip Font,Manuel Cobo-Dols,Simon Ekman,Bengt Bergman,Ronny Ohman,Anders Vikstrom,Chih-Hsin Yang,Chao-Hua Chiu,Hsu-Ching Huang,Cheng-Ta Yang,Jian Su,Gee-Chen Chang,Tsung-Ying Yang,Te-Chun Hsia,Wu-Chou Su,Shang-Yin Wu,Chin-Chou Wang,Kang-Yun Lee,Sheng-Hao Lin,Chih-Bin Lin,Jih-Hsiang Lee,Chun-Yao Huang,Samreen Ahmed,Thomas Newsom-Davis,Shobhit Baijal,Juliet Brock,Kam Zaki,Jonathan Shamash,Dionysis Papadatos-Pastos,Pooja Jain,Melanie Jane Mackean,Stephan DiSean Kendall,Ian Anderson,Dan Costin,Richard Hall,Nicholas Campbell,Saad Khan,Jonathan Dowell,Sandeep Mashru,Smitha Menon,Ahmad Raza,Li Ge,Gregory J. Riely,Nagashree Seetharamu,Laura Stampleman,Janakiraman Subramanian,Donald B. Wender,Ronald B. Natale,Viola Zhu,Sai-Hong Ignatius Ou,Rachel Sanborn,Makenzi C. Evangelist

DOI: https://doi.org/10.1200/jco.23.02747

IF: 45.3

2024-08-24

Journal of Clinical Oncology

Abstract:PURPOSE Epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.

oncology
563P Real-world Effectiveness and Safety of First-Line Osimertinib for EGFR-mutated Advanced NSCLC in China (FLOURISH Study)

J. Zhou,L. Shen,D. Lv,K. Tang,D. Zhu,Y. Zhao,K. Wang,Y. Wang,L. Xing,J. Cui,L. Ding,X. Shi,J. Zheng

DOI: https://doi.org/10.1016/j.annonc.2023.10.641

IF: 51.769

2023-01-01

Annals of Oncology

Abstract:Osimertinib, the standard first-line therapy for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), preliminarily demonstrated similar clinical effectiveness to the landmark FLAURA study in the prospective, non-interventional, real-world FLOURISH study at the first interim analysis. This report presents an updated effectiveness and safety results. A total of 500 patients were recruited into the FLOURISH study from 22 sites in China between July 27, 2020, and April 27, 2022. This analysis included 460 patients who met the eligibility criteria and received at least one dose of osimertinib after enrolment and without protocol violation into the full analysis set (FAS) for effectiveness analysis, and 495 patients who received at least one dose of osimertinib after enrolment into the safety set (SS). The data cut-off date was June 30, 2023. Of the 460 patients in FAS, the median age was 64.1 years (range: 27-88), 62.4% were female, 64.8% had comorbidities, 35.0% with CNS metastases, and 98.7% in stage IIIB-IV. The objective response rate (ORR) was 61.8% (238/385), and disease control rate (DCR) was 96.1% (370/385) in evaluable patients. With a median follow-up of 18.0 months, the 1-year progression-free survival (PFS) and 1-year overall survival (OS) rate was 79.6% (95%CI: 75.0%-83.3%) and 90.0% (95%CI: 86.8%-92.5%), respectively. In patients with CNS metastases, ORR was 63.8% (90/141), DCR was 95.0% (134/141), 1-year PFS rate was 78.9%, and 1-year OS rate was 90.1%. Moreover, patients with exon 19 deletion (n=235) had higher 1-year PFS (84.2% vs. 75.0%) and 1-year OS (93.4% vs. 86.8%) rates than patients with exon 21 L858R (n=212). Among the 495 patients in SS, 195 patients (39.4%) experienced adverse events (AEs), with 18(3.6%) of grade ≥3. AEs leading to dose interruption or discontinuation were reported in 3 (0.6%) and 12(2.4%) patients, respectively. The FLOURISH study showed consistence with FLAURA in terms of effectiveness of first-line osimertinib for Chinese patients with advanced EGFRm-NSCLC in real world setting. No new safety signals were observed. The follow-up is still ongoing and the final analysis is expected in future.
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).

Daniel Adam Breadner,Mark David Vincent,Geoffrey Liu,Jeffrey Rothenstein,Ines B. Menjak,Parneet Kaur Cheema,Rosalyn A. Juergens,Hamid Mithoowani,Puneet Bains,Ying Wang,Paul Wheatley-Price

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps9160

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:TPS9160 Background: The results of the FLAURA study established osimertinib as the new first-line standard of care for patients with the two ‘common’ types of epidermal growth factor receptor mutation-positive (EGFR+) advanced non-small-cell lung cancer (aNSCLC). Second-line (2L) treatment is typically platinum pemetrexed chemotherapy and the standard third-line (3L) treatment is docetaxel throughout much of the globe, which has a modest response rate of 7 – 15%. Previously, when first generation (1G) EGFR tyrosine kinase inhibitor (TKIs) were standard of care in the first-line setting, a number of prospective and retrospective studies examined 3L rechallenge with the same 1G EGFR TKI following 2L chemotherapy, with varying levels of success. Osimertinib is a well-tolerated EGFR TKI which is active against the T790M resistance mutation, which would have limited the efficacy of rechallenge with 1G EGFR TKIs. Methods: This is a multicentered international phase II investigator-initiated study of osimertinib in the 3L rechallenge of patients with EGFR+ aNSCLC, following 1L treatment with osimertinib and 2L therapy with platinum pemetrexed chemotherapy. A maximum of 255 patients will be enrolled. Patients with ‘common’ EGFR exon 19 deletions or L858R mutations will enroll at the start of 2L chemotherapy or 3L osimertinib rechallenge. The primary objective is 3L objective response rate (ORR) in the first 100 evaluable patients, according to RECIST 1.1. Secondary objectives include disease control rate (DCR), progression free survival (PFS), time to treatment failure, overall survival and toxicity for 3L osimertinib rechallenge. Exploratory objectives include assessment of osimertinib resistance based on serial ctDNA samples collected from all participants. The OCELOT study, NCT04335292, is actively enrolling participants. Clinical trial information: NCT04335292 .

oncology
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Masayuki Takeda,Mototsugu Shimokawa,Atsushi Nakamura,Kaname Nosaki,Yasutaka Watanabe,Terufumi Kato,Daisuke Hayakawa,Hiroshi Tanaka,Toshiaki Takahashi,Masahide Oki,Motoko Tachihara,Daichi Fujimoto,Hidetoshi Hayashi,Kakuhiro Yamaguchi,Shoichiro Yamamoto,Eiji Iwama,Koichi Azuma,Kazuo Hasegawa,Nobuyuki Yamamoto,Kazuhiko Nakagawa

DOI: https://doi.org/10.1016/j.lungcan.2023.01.011

IF: 6.081

Lung Cancer

Abstract:Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is an established standard treatment option for chemotherapy-naive patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, of such patients who have received prior treatment with a first- or second-generation EGFR TKI, only approximately half are eligible for osimertinib therapy because its indication as second-line treatment and beyond is limited to metastatic NSCLC that is positive for the T790M resistance mutation of the EGFR gene. This study was initiated at the request of a dedicated network for patients with lung cancer in Japan. Methods: We conducted a phase II study to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. The primary end point was response rate (assessed by a central imaging reviewer). Results: From August 2020 to February 2021, 55 patients from 15 institutions were enrolled in the study. The overall response for primary analysis was achieved in 16 patients (29.1 %; 95 % CI, 17.6-42.9), which exceeded the threshold response rate necessary for analysis. Stable disease was found in 16 patients (29.1 %), and progressive disease, in 18 (32.7 %). The median length of progression-free survival (PFS) was 4.07 months (95 % CI 2.10-4.30), and the rate of 12-month PFS was 17.3 %. Conclusions: Osimertinib demonstrated modest antitumor activity against progressive EGFR T790M-negative disease.
Osimertinib or EGFR-TKIs/chemotherapy in Patients with EGFR-mutated Advanced Nonsmall Cell Lung Cancer

Lei Huang,Hao Huang,Xiaoping Zhou,Jinfeng Liu,Chunrong Li,Min Fang,Junrong Wu

DOI: https://doi.org/10.1097/md.0000000000017705

IF: 1.6

2019-01-01

Medicine

Abstract:Background: The aim of this meta-analysis is to investigate the impact of Osimertinib on treatment efficacy in advanced nonsmall cell lung cancer (NSCLC). Methods: Trials comparing Osimertinib against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)/chemotherapy in patients with NSCLC with an epidermal growth factor receptor (EGFR) mutation were included, and the pooled data for progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed. Results: Analysis results based on 6 eligible trials showed that Osimertinib significantly improved the overall PFS (hazard ratio [HR] = 0.38, 95% confidence interval [CI] = 0.29–0.50), improved the OS (HR = 0.66, 95% CI = 0.48–0.89), increased the ORR (odds ratio [OR] = 1.76, 95% CI = 1.14–2.72), increased the overall DCR (OR = 1.18, 95% CI = 1.02–1.37), and reduced the grade 3 or greater AEs (relative ratio [RR] = 0.50, 95% CI = 0.33–0.75) in all subgroups except in the ORR in the Exon 19 deletion (Ex19del) and/or L858R subgroup. Compared to patients with Ex19del and/or L858R mutation, patients with the T790M mutation had the benefits of a greater PFS (41.7%), a greater ORR (80.0%), a greater DCR (71.2%), and fewer grade 3 or greater AEs (70.7%) (each P < .05). Race, sex, age, EGFR mutation, and smoking history may significantly predict additional benefits from Osimertinib, but there were no significant differences between subgroups stratified by these clinical characteristics. Conclusions: Osimertinib showed greater treatment benefit for patients with NSCLC with EGFR mutation than EGFR-TKIs/chemotherapy, especially for T790M mutation-positive patients.
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Masahiro Tsuboi,Roy S. Herbst,Thomas John,Terufumi Kato,Margarita Majem,Christian Grohé,Jie Wang,Jonathan W. Goldman,Shun Lu,Filippo de Marinis,Frances A. Shepherd,Ki Hyeong Lee,Nhieu Thi Le,Arunee Dechaphunkul,Dariusz Kowalski,Laura Bonanno,Manuel Dómine,Lynne Poole,Ana Bolanos,Yuri Rukazenkov,Yi-Long Wu

DOI: https://doi.org/10.1007/s11523-024-01034-3

2024-03-12

Targeted Oncology

Abstract:This is a summary of the original article "Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor shrinkage, and is an effective treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The ADAURA study assessed the effects of osimertinib versus placebo in patients with EGFR-mutated (exon 19 deletion or L858R) early stage (IB–IIIA) NSCLC removed by surgery (resected). Previous results from ADAURA demonstrated that patients treated with osimertinib stayed alive and cancer-free (disease-free survival) significantly longer than patients who received placebo. Recent data showed the overall length of time patients were alive after starting treatment (overall survival). In both the primary stage II–IIIA and overall stage IB–IIIA populations, patients in the osimertinib group had a significant 51% reduction in the risk of death compared with the placebo group. The data demonstrated that osimertinib after surgery significantly improved overall survival in patients with resected, EGFR-mutated, stage IB–IIIA NSCLC.

oncology
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer

Andre Verhoek,Parneet Cheema,Barbara Melosky,Benoit Samson,Frances A Shepherd,Filippo de Marinis,Thomas John,Yi-Long Wu,Bart Heeg,Nadia Van Dalfsen,Benjamin Bracke,Miguel Miranda,Simon Shaw,Daniel Moldaver

DOI: https://doi.org/10.1007/s41669-023-00396-0

Abstract:Background: For many patients with resected epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), current standard of care (SoC) is adjuvant chemotherapy; however, disease recurrence remains high. Based on positive results from ADAURA (NCT02511106), adjuvant osimertinib was approved for treatment of resected stage IB‒IIIA EGFRm NSCLC. Objective: The aim was to assess the cost-effectiveness of adjuvant osimertinib in patients with resected EGFRm NSCLC. Methods: A five-health-state, state-transition model with time dependency was developed to estimate lifetime (38 years) costs and survival of resected EGFRm patients treated with adjuvant osimertinib or placebo (active surveillance), with/without prior adjuvant chemotherapy, using a Canadian Public Healthcare perspective. Transitions between health states were modeled using ADAURA and FLAURA (NCT02296125) data, Canadian life tables, and real-world data (CancerLinQ Discovery®). The model used a 'cure' assumption: patients remaining disease free for 5 years after treatment completion for resectable disease were deemed 'cured.' Health state utility values and healthcare resource usage estimates were derived from Canadian real-world evidence. Results: In the reference case, adjuvant osimertinib treatment led to a mean 3.20 additional quality-adjusted life-years (QALYs; (11.77 vs 8.57) per patient, versus active surveillance. The modeled median percentage of patients alive at 10 years was 62.5% versus 39.3%, respectively. Osimertinib was associated with mean added costs of Canadian dollars (C$)114,513 per patient and a cost/QALY (incremental cost-effectiveness ratio) of C$35,811 versus active surveillance. Model robustness was demonstrated by scenario analyses. Conclusions: In this cost-effectiveness assessment, adjuvant osimertinib was cost-effective compared with active surveillance for patients with completely resected stage IB‒IIIA EGFRm NSCLC after SoC.

Neuropathological diagnosis of Alzheimer disease.

Middleware-Based Failure Detection and Recovery Services for Fault-Tolerant E-services

Osimertinib As Neoadjuvant Therapy in Patients with EGFR-mutant Resectable Stage II-IIIB Lung Adenocarcinoma (NEOS): A Multicenter, Single-Arm, Open-Label Phase 2b Trial.

New 3 alpha-hydroxy steroid-nicotinamide-adenine dinucleotide oxidoreductase activity in crystalline enzyme preparations.

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB–IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Adjuvant Osimertinib in Patients with Stage IB to IIIA EGFR Mutation-Positive NSCLC after Complete Tumor Resection: ADAURA China Subgroup Analysis

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

563P Real-world Effectiveness and Safety of First-Line Osimertinib for EGFR-mutated Advanced NSCLC in China (FLOURISH Study)

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Osimertinib or EGFR-TKIs/chemotherapy in Patients with EGFR-mutated Advanced Nonsmall Cell Lung Cancer

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer